Phenotypes associated with this allele

• Allele Symbol: Tg(tetO-PyVT,-cre)1Mul
• Allele Name: transgene insertion 1, William Muller
• Allele ID: MGI:5805223
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(MMTV-rtTA)1Lach/0 Tg(tetO-PyVT,-cre)1Mul/0	FVB/N-Tg(MMTV-rtTA)1Lach Tg(tetO-PyVT,-cre)#Mul	MGI:5903421

Genotype
MGI:5903421

cx1

• Allelic Composition: Tg(MMTV-rtTA)1Lach/0; Tg(tetO-PyVT,-cre)1Mul/0
• Genetic Background: FVB/N-Tg(MMTV-rtTA)1Lach Tg(tetO-PyVT,-cre)#Mul

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased mammary adenocarcinoma incidence ( J:231983 )

• mammary tumors in doxycycline treated virgin females progress to carcinoma

increased mammary gland tumor incidence in virgin females ( J:231983 )

• 74.4% of virgin females induced with doxycycline between 8 and 16 weeks of age develop multifocal mammary tumors within 16 days of induction and a further 12.8% of females develop tumors between 17 and 365 days post-induction

• 12.8% of virgin females induced with doxycycline remain tumor-free after 1 year of induction

• average tumor onset is 22 days post doxycycline induction

• mammary glands of doxycycline treated mice show all stages of tumorigenesis, progressing from hyperplasia, to mammary intraepithelial neoplasia/adenoma, and finally to early and late carcinoma

• discontinuing doxycycline treatment in mice bearing end-stage mammary tumors results in tumor regression but eventually recurrence of doxycycline-independent masses is seen

increased metastatic potential ( J:231983 )

• mammary tumors from doxycycline induced mice metastasize to the lungs

• however, no correlation between the extent of metastasis and tumor burden is seen

integument

increased mammary adenocarcinoma incidence ( J:231983 )

• mammary tumors in doxycycline treated virgin females progress to carcinoma

increased mammary gland tumor incidence in virgin females ( J:231983 )

• 74.4% of virgin females induced with doxycycline between 8 and 16 weeks of age develop multifocal mammary tumors within 16 days of induction and a further 12.8% of females develop tumors between 17 and 365 days post-induction

• 12.8% of virgin females induced with doxycycline remain tumor-free after 1 year of induction

• average tumor onset is 22 days post doxycycline induction

• mammary glands of doxycycline treated mice show all stages of tumorigenesis, progressing from hyperplasia, to mammary intraepithelial neoplasia/adenoma, and finally to early and late carcinoma

• discontinuing doxycycline treatment in mice bearing end-stage mammary tumors results in tumor regression but eventually recurrence of doxycycline-independent masses is seen

endocrine/exocrine glands

increased mammary adenocarcinoma incidence ( J:231983 )

• mammary tumors in doxycycline treated virgin females progress to carcinoma

increased mammary gland tumor incidence in virgin females ( J:231983 )

• 74.4% of virgin females induced with doxycycline between 8 and 16 weeks of age develop multifocal mammary tumors within 16 days of induction and a further 12.8% of females develop tumors between 17 and 365 days post-induction

• 12.8% of virgin females induced with doxycycline remain tumor-free after 1 year of induction

• average tumor onset is 22 days post doxycycline induction

• mammary glands of doxycycline treated mice show all stages of tumorigenesis, progressing from hyperplasia, to mammary intraepithelial neoplasia/adenoma, and finally to early and late carcinoma

• discontinuing doxycycline treatment in mice bearing end-stage mammary tumors results in tumor regression but eventually recurrence of doxycycline-independent masses is seen

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:231983